Stocktoria
PepGen Inc. PEPG
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2022-05-06
PepGen Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $71.0M | $76.5M | $68.1M | $54.1M | $19.0M |
| Operating income | -$93.6M | -$97.7M | -$84.8M | -$68.3M | -$27.1M |
| Income tax | $48,865 | -$617,000 | $73,000 | $3.7M | $0 |
| Net income | -$89.7M | -$90.0M | -$78.6M | -$69.1M | -$27.3M |
| EPS (diluted) | $-2.12 | $-2.85 | $-3.30 | $-4.42 | $-30.27 |
| Operating cash flow | -$81.6M | -$82.4M | -$69.0M | -$59.3M | -$22.6M |
| Free cash flow | -$81.9M | -$82.9M | -$71.6M | -$63.0M | -$23.1M |
| Cash & equivalents | $60.5M | $49.4M | $80.8M | $181.8M | $132.9M |
| Total assets | $173.9M | $150.9M | $143.1M | $217.4M | $143.6M |
| Total liabilities | $26.5M | $32.3M | $34.6M | $37.8M | $10.5M |
| Shareholders' equity | $147.4M | $118.6M | $108.4M | $179.6M | -$32.1M |
Source: SEC EDGAR filings · CIK 0001835597 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.